fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Azithromycin

All products: Limited Use (codes 549)

PMS-Azithromycin · DIN 02261642 · 600 mg · tablet

Limited Use, Reason for Use code 549 requiredDormant since July 31, 2026 · checked November 17, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 549 required
Write on scriptReason for Use code 549 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 549
Reason for Use code 549 For the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infections. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
PMS-Azithromycin · DIN 02261642 Manufacturer: Pharmascience Inc.; listing date 2011-10-25 Health Canada: Dormant since 2026-07-31 · brand PMS-AZITHROMYCIN · ATC J01FA10 AZITHROMYCIN · form Tablet · route Oral · ingredients AZITHROMYCIN 600 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Azithromycin: Formulary list price $10.67 per unit (the source does not state the unit; exact figure $10.6652). What the ministry pays, not the patient.

Ministry pays: $10.6652 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02261642)

Source record
DIN 02261642: PMS-Azithromycin Raw flags: sec12=Y, sec3=Y Item: 081212028; group id 20; item number 0031; lccId 00313; manufacturer id PMS Source form: Tab; strength: 600mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.6652; ministry $10.6652 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02261642 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74702
Interchangeable products
Zithromax · DIN 02231143 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since July 31, 2026 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01FA): coverage varies; not interchangeable

  • Clarithromycin (Biaxin XL): general benefit, not a benefit
  • Erythromycin base (Erythromid): general benefit, not a benefit
  • Erythromycin estolate (Ilosone): general benefit, not a benefit
  • Erythromycin ethylsuccinate (Ees-200): general benefit, not a benefit
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CLARITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE 08:12:12 Erythromycins

CLARITHROMYCIN

· 25 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 500mg, 125mg/5mL, 250mg/5mL, 250mg · ER Tab, Ped Gran, Susp, Tab

ERYTHROMYCIN BASE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ERYTHROMYCIN ESTOLATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg/mL · O/L

ERYTHROMYCIN ETHYLSUCCINATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg/mL, 80mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: disseminated mycobacterium avium complex
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. RIFABUTIN · Limited Use, codes 103, 104 (1), Temporary benefit (1) • the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection (CD4+ cell count 200/mm3 with an AIDS defining diagnosis, or CD4+ cell count  100/mm3 without an AIDS defining diagnosis). PM: https://pdf.hres.ca/dpd_pm/00073866.PDF; date SEPT 24, 2003; DIN 02063786; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications pms-AZITHROMYCIN (azithromycin) is indicated in adults for treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions. As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, see 4 Dosage and Administration for specific dosing recommendations. Because some strains are resistant to azithromycin, when applicable, appropriate culture and susceptibility tests should be initiated before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with pms-AZITHROMYCIN may be initiated before results of these tests are known; once the results become available, antibiotic treatment should be adjusted accordingly. Pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β-hemolytic streptococci) occurring in individuals who cannot use first line therapy. NOTE: Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of strep… https://pdf.hres.ca/dpd_pm/00085669.PDF PM date: AUG 7, 2026 Source product: PMS-AZITHROMYCIN; DIN 02261634; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)